NoV GI.1/GII.4 Bivalent VLP Vaccine
LV03-104
Phase 1 mab completed
Quick answer
NoV GI.1/GII.4 Bivalent VLP Vaccine for Gastroenteritis is a Phase 1 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Gastroenteritis
- Phase
- Phase 1
- Modality
- mab
- Status
- completed